Abstract
Extensive research over the past two decades in tumor immunology has shown that immune reactivity to tumor antigens can restrict tumor growth and/or metastasis, especially when tumor burden is low. These observations in experimental models have been translated into clinical studies involving both active and passive forms of immunotherapies. While immune responses to specific tumor antigens can be detected in patients with various types of cancers, responses to any single antigen seldom correlate directly with a clinical response to tumors; however, some clinical regressions of solid tumors have been reported with certain types of cancer vaccines. While passive immunotherapies with antibody to tumor antigens (Avastin®, Herceptin®, Erbitux®, RituxanTM, BexxarTM) are being used to treat selected types of cancers, active immunotherapies may be better suited to potentially elicit a sustained immune response, particularly when administered in an adjuvant setting. This review covers the potential and issues with specific active immunotherapies (SAI) for the treatment of cancer.
Keywords: Tumor antigens, Active immunotherapy, Cancer vaccines, Clinical trials
Reviews on Recent Clinical Trials
Title: Specific Active Immunotherapy of Cancer: Potential and Perspectives
Volume: 1 Issue: 3
Author(s): Roopa Srinivasan and Dennis E. Van Epps
Affiliation:
Keywords: Tumor antigens, Active immunotherapy, Cancer vaccines, Clinical trials
Abstract: Extensive research over the past two decades in tumor immunology has shown that immune reactivity to tumor antigens can restrict tumor growth and/or metastasis, especially when tumor burden is low. These observations in experimental models have been translated into clinical studies involving both active and passive forms of immunotherapies. While immune responses to specific tumor antigens can be detected in patients with various types of cancers, responses to any single antigen seldom correlate directly with a clinical response to tumors; however, some clinical regressions of solid tumors have been reported with certain types of cancer vaccines. While passive immunotherapies with antibody to tumor antigens (Avastin®, Herceptin®, Erbitux®, RituxanTM, BexxarTM) are being used to treat selected types of cancers, active immunotherapies may be better suited to potentially elicit a sustained immune response, particularly when administered in an adjuvant setting. This review covers the potential and issues with specific active immunotherapies (SAI) for the treatment of cancer.
Export Options
About this article
Cite this article as:
Srinivasan Roopa and Van Epps E. Dennis, Specific Active Immunotherapy of Cancer: Potential and Perspectives, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250113
DOI https://dx.doi.org/10.2174/157488706778250113 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Applications of Solid-State Fermentation Process in Biological Detoxification of Industrial Wastes
Current Biochemical Engineering (Discontinued) SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery The Effectiveness of Condoms for the Prevention of Sexually Transmitted Diseases
Current Women`s Health Reviews Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Current Perspectives on Cytokines for Anti-retroviral Therapy in AIDS Related B-cell Lymphomas
Current Drug Targets - Infectious Disorders Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Acetogenin Extracted from <i>Annona muricata</i> Prevented the Actions of EGF in PA-1 Ovarian Cancer Cells
Protein & Peptide Letters MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Applications and Toxicity of Silver Nanoparticles: A Recent Review
Current Topics in Medicinal Chemistry Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Physiology of Folic Acid in Health and Disease
Current Drug Metabolism